Sign Up
Stories
Biopharma Breakthroughs and Safety Advancements
Share
Biotech and Gene Therapy Appointments an...
Innovations Shaping Future Healthcare
Innovations in Biopharma and Healthcare
4D Molecular Therapeutics Raises $300 Mi...
AB-2100 Phase 1/2 Trial Initiated
AI Partnerships Drive Drug Discovery
Overview
API
Biopharma companies Vividion Therapeutics and Roche publish groundbreaking Nature paper on a clinical-stage inhibitor for Werner helicase. Aldeyra Therapeutics announces preclinical data updates and plans for a pivotal clinical trial in retinitis pigmentosa. Mission Bio introduces new translocation analysis enhancing gene-edited cell product safety assessment.
Ask a question
How could Mission Bio's translocation analysis innovation influence the development and commercialization of gene-edited cell therapies?
How might the discoveries by Vividion and Roche impact the future treatment of diseases related to Werner helicase?
What are the implications of Aldeyra Therapeutics' planned pivotal trial in retinitis pigmentosa for patient care and drug development?
Article Frequency
0.2
0.4
0.6
0.8
1.0
Jan 2024
Feb 2024
Mar 2024
Coverage